Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11241316 | 0.81 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL7118195 | 0.80 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL100732 | 0.80 | CYP1A2 (0.76) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL224653 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL30320250 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL19779893 | 0.79 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL514630 | 0.76 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL11213795 | 0.76 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL1888696 | 0.76 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL4968573 | 0.76 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102166403-B | Multilayer core golf ball | ACUSHNET CO | 2015-02-18 | — | — | CN | disclosed |
| EP-1996541-B1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8044242-B2 | 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| CN-102166402-A | Multilayer core golf ball | ACUSHENT COMPANY | 2011-08-31 | — | — | CN | disclosed |
| CN-102166403-A | Multilayer core golf ball | ACUSHENT COMPANY | 2011-08-31 | — | — | CN | disclosed |
| CN-102166404-A | Multilayer core golf ball | ACUSHENT COMPANY | 2011-08-31 | — | — | CN | disclosed |
| EP-1910298-B1 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
| EP-1996541-A1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1910298-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007103996-A1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| CN-1071324-C | Process and intermediates for preparing 3- (1-piperazinyl) -1, 2-benzisothiazole | PFIZER (US) | 2001-09-19 | — | — | CN | disclosed |
| CN-1201457-A | Process and intermediates for preparing 30(1-piperazinyl)-1,2-benzisothiazole | PFIZER (US) | 1998-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | CYP1A2 409/4885CYP3A4 201/4885CYP2C9 81/4885 |
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F12 | CYP1A2 224/4885CYP3A4 349/4885CYP2C9 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.